Antlia Bioscience, Inc.
ENCINITAS, CA · Founded 2020 · CIK 0001829522 · Biotech · Private
Long-acting therapeutic formulations for cardiometabolic diseases
antliabio.com →- Grants
- $1000K
- 1 award
- Sector median: 1
- Raised
- $6.9M
- 3 Form D · Jun 2026
- 4 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $207,000 | |
| Private capital raised | Form D · SEC | $680,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension | $999,998 | |
| Private capital raised | Form D · SEC | $6,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1887 | Protocol 46 Inc. | — | $410K |
| 1888 | RETROVIROX, INC. | — | — |
| 1889 | Cotinga Pharmaceuticals Inc. | — | $3.0M |
| 1890 | Antlia Bioscience, Inc. | — | $6.9M |
| 1891 | PLEOPHARMA, INC. | — | $17M |
| 1892 | D2G ONCOLOGY, INC. | — | $6.6M |
| 1893 | OCATA THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ben AuspitzDirector
- Carlos EcheverriaDirector
- Brian JohnsonDirector · Executive Officer
- Ankit MahadeviaDirector · Executive Officer
- Nihal SinhaDirector
- Martin TaylorDirector
Patents
- Modified B-type Natriuretic Peptideapplication
- Modified B-type Natriuretic Peptideapplication
- Modified Urocortin 3application
- Modified B-type Natriuretic Peptideapplication
- Modified B-type Natriuretic Peptideapplication
- Modified B-type Natriuretic Peptideapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.